Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US

Highlights • Cytomegalovirus (CMV) infection is the leading cause of birth defects in the US. • CMV vaccines targeting seronegative women are currently in clinical development. • The optimal age for vaccination depends on the duration of vaccine protection. • For most scenarios, it is optimal to vac...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2016-01, Vol.34 (2), p.225-229
Hauptverfasser:	Alfaro-Murillo, Jorge A, Townsend, Jeffrey P, Galvani, Alison P
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Age Aged Aged, 80 and over Allergy and Immunology Breast feeding Breastfeeding & lactation Child Child, Preschool Cytomegalovirus Cytomegalovirus (CMV) Cytomegalovirus Infections - diagnosis Cytomegalovirus Infections - prevention & control Cytomegalovirus Vaccines - administration & dosage Disease Transmission, Infectious - prevention & control Female Hearing loss Humans Immigration Immunization Immunization Schedule Infant Infant, Newborn Infants Infections Infectious Disease Transmission, Vertical - prevention & control Male Mass Screening - methods Middle Aged Mothers Population Screening Transmission United States Vaccination Vaccines Visual impairment Womens health Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Cytomegalovirus (CMV) infection is the leading cause of birth defects in the US. • CMV vaccines targeting seronegative women are currently in clinical development. • The optimal age for vaccination depends on the duration of vaccine protection. • For most scenarios, it is optimal to vaccinate women from 19 to 21 years of age. • If the duration of vaccine protection is short, it is optimal to vaccinate infants.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2015.11.039